ArticlePloS one2013
Genomic investigation into strain heterogeneity and pathogenic potential of the emerging gastrointestinal pathogen Campylobacter ureolyticus.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Species Delineation and Comparative Genomics within theJournal of clinical microbiology · 2023Review
- Article
- The cancer microbiome atlas: a pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants.Cell host & microbe · 2021Article
- Complete Genome Sequence Reveals Evolutionary and Comparative Genomic Features ofMicroorganisms · 2020Article
- Pathogenomics of EmergingClinical microbiology reviews · 2019Review
- The Clinical Importance ofFrontiers in cellular and infection microbiology · 2018Review
- Fic Proteins ofFrontiers in microbiology · 2017Article
- Incidence ofGut pathogens · 2017Article
- Clinical relevance of infections with zoonotic and human oral species of Campylobacter.Journal of microbiology (Seoul, Korea) · 2016Review
- Zonula occludens toxins and their prophages in Campylobacter species.Gut pathogens · 2016Article
- Complete Genome Sequence of the Campylobacter ureolyticus Clinical Isolate RIGS 9880.Genome announcements · 2015Article
- Oral Campylobacter species: Initiators of a subgroup of inflammatory bowel disease?World journal of gastroenterology · 2015Review
- Under the microscope: From pathogens to probiotics and back.Bioengineered · 2015Review
- Campylobacter ureolyticus: a portrait of the pathogen.Virulence · 2014Review
- Draft Genome Sequence of Campylobacter ureolyticus Strain CIT007, the First Whole-Genome Sequence of a Clinical Isolate.Genome announcements · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent detection and isolation of C. ureolyticus from patients with diarrhoeal illness and inflammatory bowel diseases warrants further investigation into its role as an emerging pathogen of the human gastrointestinal tract. Regarding the pathogenic mechanisms employed by this species we provide the first whole genome analysis of two C. ureolyticus isolates including the type strain. Comparative analysis, subtractive hybridisation and gene ontology searches against other Campylobacter species identifies the high degree of heterogenicity between C. ureolyticus isolates, in addition to the identification of 106 putative virulence associated factors, 52 of which are predicted to be secreted. Such factors encompass each of the known virulence tactics of pathogenic Campylobacter spp. including adhesion and colonisation (CadF, PEB1, IcmF and FlpA), invasion (ciaB and 16 virB-virD4 genes) and toxin production (S-layer RTX and ZOT). Herein, we provide the first virulence catalogue for C. ureolyticus, the components of which theoretically provide this emerging species with sufficient arsenal to establish pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.